Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleigha Lawless

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The Oncologist|September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patientsTristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
JAMA Dermatology|March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint InhibitorsKylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaRachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Nature Communications|August 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trialMeghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Buoyant mass reveals distinct T cell states predictive of checkpoint responseJiaquan Yu, Ye Zhang, Sarah M Duquette, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
Cancer Immunology Research|January 9, 2025
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor SpheroidsYi Sun, Luke Maggs, Apekshya Panda, et al.
Biorxiv : the Preprint Server for Biology|October 4, 2023
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Nature|November 7, 2024
Immune responses in checkpoint myocarditis across heart, blood and tumourSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Oncologist|September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patientsTristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
JAMA Dermatology|March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint InhibitorsKylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaRachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Nature Communications|August 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trialMeghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Buoyant mass reveals distinct T cell states predictive of checkpoint responseJiaquan Yu, Ye Zhang, Sarah M Duquette, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
Cancer Immunology Research|January 9, 2025
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor SpheroidsYi Sun, Luke Maggs, Apekshya Panda, et al.
Biorxiv : the Preprint Server for Biology|October 4, 2023
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Nature|November 7, 2024
Immune responses in checkpoint myocarditis across heart, blood and tumourSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.
Pageof 3